Effectiveness And Safety Of Baricitinib In Alopecia Areata: A Prospective Cohort Study

    November 2025 in “ Journal of Dermatological Treatment ”
    Daniel Muñoz‐Barba, Carmen García‐Moronta, Sofia Haselgruber-de Francisco … Salvador Arias-Santiago
    Studysummary This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 22

    1. Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients Acta Dermato Venereologica · 2025
    2. Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study Journal of the European Academy of Dermatology and Venereology · 2025
    3. Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region International Journal of Dermatology · 2025
    4. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    5. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    6. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    7. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    8. Predictors And Management Of Inadequate Response To JAK Inhibitors In Alopecia Areata American Journal of Clinical Dermatology · 2024
    9. Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients Dermatology Practical & Conceptual · 2024
    10. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    11. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    12. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients Acta dermato-venereologica · 2024
    13. 67 Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the ALLEGRO Phase 2b/3 and Ongoing Phase 3 ALLEGRO-LT Studies Journal of Investigative Dermatology · 2023
    14. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    15. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    16. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    17. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata JAMA Dermatology · 2023
    18. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    19. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    20. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
    21. Italian Guidelines in Diagnosis and Treatment of Alopecia Areata Giornale italiano di dermatologia e venereologia · 2019
    22. SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss Journal of The American Academy of Dermatology · 2016